Pharmaceutical giant Eli Lilly enters a strategic collaboration potentially worth up to $1.93 billion with biotech firm Repertoire Immune Medicines, aiming to develop precision treatments for autoimmune diseases that move beyond broad immunosuppression.
Eli Lilly's CEO sees Medicare's new policy covering obesity treatments as a pivotal moment, poised to unlock access for millions of beneficiaries to its incoming oral drug, orforglipron, and intensify the market battle with Novo Nordisk.
Despite posting impressive revenue and subscriber growth in 2025, Netflix faces a critical headwind: its share of viewer engagement is growing at a fraction of the overall streaming market's pace, signaling intensified competition for attention.
Lyft shares have dramatically outperformed the S&P 500, climbing nearly 20% in six months. While rider growth and improving cash flow paint an optimistic picture, underlying margin pressures reveal the intense competition in the ride-hailing sector.
Pharmaceutical giant Eli Lilly announces a major $3.5 billion manufacturing expansion for its weight-loss drugs and enters two strategic research collaborations in gene editing and immunology, signaling aggressive growth plans amid a recent stock valuation dip.
Advanced Micro Devices (AMD) is set to report its fourth-quarter earnings after the bell Tuesday, with Wall Street keenly watching for updates on its AI chip strategy and data center growth against a backdrop of fierce competition.
Mondelez International merges its financial and operational leadership under CFO Luca Zaramella, a move analysts say aims to tighten cost control and execution amid intense competition and commodity pressures.
The healthcare behemoth's robust 2025 results and 2026 guidance signal a landmark year ahead, as it navigates patent expirations and pricing pressures while maintaining its coveted dividend king status.
Despite fried chicken chains leading fast-food growth, one of Popeyes' largest franchisees has shuttered 17 locations and entered Chapter 11, highlighting the sector's uneven fortunes amid fierce competition and financial pressures.
Novo Nordisk's newly launched oral GLP-1 drug, amycretin, has seen explosive initial demand in the U.S., potentially setting the stage for a significant financial turnaround and stock rally after a challenging previous year.
As Tilray Brands' stock languishes near multi-year lows, a deep dive into its valuation metrics suggests a significant discount. But with the cannabis sector facing headwinds, is this a genuine opportunity for investors, or a sign of deeper troubles?
Viasat shares have rocketed 31% in a month, reigniting investor debate over whether the satellite communications firm is a hidden gem or a momentum-driven play facing stiff competition from SpaceX's Starlink and Amazon's Project Kuiper.
Facing stiff competition, Verizon is deploying AI at scale and restructuring its operations—funded partly by recent layoffs—to simplify customer interactions and rebuild loyalty in a saturated market.
Investors face a classic choice between AbbVie's steady dividends and Abivax's high-risk, high-reward potential as both target lucrative immunology markets.
After the COVID-19 windfall subsided, Pfizer CEO Albert Bourla is steering the pharmaceutical giant into a high-stakes, $23 billion pivot to cancer research. Facing a looming patent cliff and plummeting vaccine revenue, Bourla is betting on scientific innovation to secure the company's future—and redefine cancer treatment.
Baidu's flagship AI assistant, Ernie, has surpassed 200 million monthly active users, a milestone reported by the Wall Street Journal. The growth underscores Baidu's deepening integration of AI across its ecosystem amid fierce competition with domestic tech rivals.
While the healthcare sector has surged 17.4% in six months, outpacing the S&P 500, regulatory headwinds and valuation concerns demand a selective approach. We examine one stock with a durable edge and two facing significant challenges.
A four-advisor team managing $1 billion in client assets has left Merrill Lynch to join Raymond James' employee channel, underscoring the intensifying competition for top wealth management talent.
While robust cash generation is a hallmark of a healthy business, it doesn't automatically translate to a sound investment. We examine three companies with strong free cash flow margins where valuation and strategic concerns give investors pause.
Former House Speaker Nancy Pelosi has sold between $1 million and $5 million worth of Disney shares, a move that spotlights the entertainment giant's struggle to navigate declining linear TV revenues and intense streaming competition, even as its parks and direct-to-consumer segments show resilience.
